arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

AYTU BIOPHARMA, INC

AYTU
$2.21 ▼ -0.02 (-0.67%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
86 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

AYTU BIOPHARMA, INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 6.4% ↗
Op. Margin -4.8% ↗
ROIC -6.6% ↗
FCF / Share None
Trailing P/E 8.5x
Price / Book 0.7x
FCF Yield —
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Sep 23, 2026.

86-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.11M
↑ +6.4% —
Net Income Profit after all expenses
$-15.00K
↑ +99.9% —
Operating Margin Operating profit as % of sales
-4.8%
↑ +85.3% 9th
FCF / Share Free cash flow per share
$-0.40
↓ -209.2% —
Long-Term Debt Long-term obligations
$9.10M
↓ -4.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
18
Returns ↑
15
Financial Health ↑
48
Cash Quality
17

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 22 years · 86 quarters